PHATHOM PHARMACEUTICALS, INC. (PHAT)

Every figure this model derived for PHAT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 219,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 182,478,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 295,915,000 AssetsCurrent 2026-06-30
current liabilities 153,777,000 LiabilitiesCurrent 2026-06-30
equity -344,273,000 StockholdersEquity 2026-06-30
interest expense 63,427,000 InterestExpenseNonoperating 2026-06-30
ocf -36,693,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 239,663,000 Revenues 2026-06-30
sbc 27,153,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PHAT on one particular measure came for.

RatioValue
cash operating margin-5.42
current ratio2.54
current ratio reported1.92
deferred revenue growth73.2
dilution pct15.43
fcf margin-15.4
interest cover-0.64
operating margin-16.96
owner earnings margin-26.73
revenue growth110.16
revenue growth per share82.06
rule of 4093.2
sbc pct revenue11.33

What to be careful about

What this model itself distrusts about PHAT's figures. Written by the derivation as it ran, not added afterwards.